Basecamp Research reported EDEN, an evolutionary AI family, can design enzymes that enable programmable insertion of large DNA sequences at specified genomic sites, demonstrating insertion at over 10,000 disease‑related loci in lab assays. The company showed EDEN‑designed payload integration produced CAR T cells with >90% tumor clearance in vitro and claimed broad modality generality across peptides and gene editors. The work is described in a preprint and accompanied by an undisclosed NVentures investment; it has not been peer reviewed. Basecamp frames EDEN as a platform to overcome limits of current CRISPR approaches that are constrained to small edits, potentially opening new therapeutic targets for gene‑replacement strategies.